India has moved a decisive step closer to having its first tetravalent dengue vaccine on the market after a Subject Expert Committee (SEC) under the Drugs Controller General of India (DCGI) recommended approving Takeda Biopharmaceuticals' Dengue Tetravalent Vaccine (TDV) for import and use in individuals aged 4 to 60 years.
The recommendation came out of a hybrid SEC meeting held on March 19, 2026, following the company's submission of a complete Phase III clinical study report for the Indian population, a requirement the committee had set at its earlier sitting in August last year.
A Long Road, Nearly Complete
Takeda's path to India has been methodical. The company has run twenty trials globally nine Phase III, six Phase II, and five Phase I, enrolling more than 28,000 subjects across dengue-endemic and non-endemic countries, spanning age groups from eighteen months to sixty years. The pivotal global trial, DEN-301, tracked 20,099 participants across eight countries including Brazil, Thailand, and Sri Lanka over four and a half years, generating a robust efficacy dataset that formed the backbone of regulatory submissions worldwide.
By the time Takeda walked into the March 19 meeting, the vaccine had already been approved in 41 countries, including the European Union, the United Kingdom, Switzerland, Indonesia, Malaysia, and Thailand. In the EU, it is cleared for use from four years of age. It also carries WHO pre-qualification status, with a WHO-indicated use from six years onward.
Since its global launch, approximately 24.4 million doses have been distributed, a real-world track record the committee could not ignore.
What the India Trial Showed
For the India-specific filing, Takeda conducted a randomised, double-blind, placebo-controlled Phase III study across 480 healthy participants aged 4 to 60 years, divided into two cohorts covering children, adolescents, and adults. The study was designed to assess safety and immunogenicity in the Indian population specifically, not simply to rely on the global data.
The results, as presented to the committee, showed the vaccine was well tolerated, safe, and immunogenic across all age groups studied. Post-marketing surveillance data from global markets further reassured the panel: the safety profile seen after launch has remained consistent with what was observed in clinical trials, with no new significant safety signals emerging in the risk categories identified in Takeda's risk management plan.
Conditions Attached
The SEC did not hand Takeda a blank cheque. Alongside the recommendation for new drug permission, the committee stipulated that the company must conduct a post-marketing safety and effectiveness study in the Indian population within six months of the vaccine's introduction into the Indian market. It is a standard but important safeguard, real-world Indian data on both safety and effectiveness will eventually need to feed back into the regulatory record.
Why This Matters
Dengue is not a peripheral concern in India. The country consistently ranks among the highest burden nations globally, with millions of suspected cases reported annually and significant under-reporting widely acknowledged. A licensed tetravalent vaccine, one that targets all four dengue serotypes could materially alter India's public health calculus, particularly for children in high-transmission zones.
The WHO's current position recommends dengue vaccine introduction in routine immunisation programmes for individuals aged 6 to 16 in areas where dengue transmission poses a significant public health problem, and notably, without requiring pre-vaccination screening. India's expert committee went slightly broader, recommending approval for the 4-to-60 age band, aligning with the EU label rather than the more conservative WHO floor.
With the SEC recommendation now on record, the file moves to the DCGI for the final approval decision. If granted, Takeda's TDV would become the first dengue vaccine cleared for widespread use across age groups in India, a milestone years in the making.
